Literature DB >> 2771070

Effect of age at onset on progression and mortality in Parkinson's disease.

S G Diamond1, C H Markham, M M Hoehn, F H McDowell, M D Muenter.   

Abstract

We examined longitudinal disability scores in 54 patients with Parkinson's disease followed for 6 years at UCLA. We sorted data into 3 groups based on age at onset of symptoms: group A, onset under 50 years; group B, 50 to 59 years; group C, 60 years or older. There were no significant differences between groups initially. All 3 groups improved dramatically when levodopa was given, but group A showed significantly less disability in years 4, 5, and 6 than did group C. The groups did not differ with respect to side effects. To determine if age at onset affected mortality, we sorted records from 4 geographically diverse centers into the same 3 groups. Results on 359 patients followed for 3,314 person-years, covering a period of 17 years after onset of symptoms, showed that group A had the most favorable observed-to-expected mortality ratio, 1.82, compared with 2.17 and 2.20 for groups B and C respectively, but the difference was not statistically significant. Results from the disability analyses indicate that patients with onset of Parkinson's disease under 50 years of age may have a more favorable prognosis than those whose symptoms begin in later years.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2771070     DOI: 10.1212/wnl.39.9.1187

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  29 in total

1.  Estimated life expectancy of Parkinson's patients compared with the UK population.

Authors:  Lianna S Ishihara; Anne Cheesbrough; Carol Brayne; Anette Schrag
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-03-30       Impact factor: 10.154

2.  Towards an Age-Phenome Knowledge-base.

Authors:  Nophar Geifman; Eitan Rubin
Journal:  BMC Bioinformatics       Date:  2011-06-08       Impact factor: 3.169

3.  Redefining meaningful age groups in the context of disease.

Authors:  Nophar Geifman; Raphael Cohen; Eitan Rubin
Journal:  Age (Dordr)       Date:  2013-01-27

4.  Prevalence of non-motor symptoms in young-onset versus late-onset Parkinson's disease.

Authors:  Vladana Spica; Tatjana Pekmezović; Marina Svetel; Vladimir S Kostić
Journal:  J Neurol       Date:  2012-07-22       Impact factor: 4.849

5.  A deep learning approach for prediction of Parkinson's disease progression.

Authors:  Afzal Hussain Shahid; Maheshwari Prasad Singh
Journal:  Biomed Eng Lett       Date:  2020-04-16

Review 6.  Staging neurodegenerative disorders: structural, regional, biomarker, and functional progressions.

Authors:  Trevor Archer; Richard M Kostrzewa; Richard J Beninger; Tomas Palomo
Journal:  Neurotox Res       Date:  2011-02       Impact factor: 3.911

7.  Age of onset: can we rely on essential tremor patients to report this? Data from a prospective, longitudinal study.

Authors:  Elan D Louis
Journal:  Neuroepidemiology       Date:  2012-10-24       Impact factor: 3.282

Review 8.  Therapy of Parkinson's Disease Subtypes.

Authors:  Connie Marras; K Ray Chaudhuri; Nataliya Titova; Tiago A Mestre
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

9.  Does ageing aggravate parkinsonian disability?

Authors:  J Blin; B Dubois; A M Bonnet; M Vidailhet; M Brandabur; Y Agid
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-09       Impact factor: 10.154

10.  The association between symptoms of sexual dysfunction and age at onset in Parkinson's disease.

Authors:  Tuba Özcan; Erdal Benli; Feriha Özer; Esra Yancar Demir; Yasemin Kaya; Ali Ayyıldız
Journal:  Clin Auton Res       Date:  2016-05-17       Impact factor: 4.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.